News for BioCryst Pharmaceuticals, Inc. (BCRX)

**media[653950]**

BioCryst Pharmaceuticals (BCRX) has achieved a significant milestone with the approval of ORLADEYO for routine prevention of hereditary angioedema (HAE) attacks

**media[647609]**

Shares of BioCryst Pharmaceuticals Inc (BCRX) surged 3.59% in mid-day trading on Jun 3. The stock reached an intraday high of $11.12, up from its previous clo

Summary BioCryst Pharmaceuticals Inc (BCRX), a global biotechnology company, announced on June 3, 2025, that its board's compensation committee has granted rest

RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. ( BCRX) today announced that the compensation committee of BioC

BioCryst Pharmaceuticals (BCRX) has awarded restricted stock units (RSUs) to seven new employees. Collectively, these units encompass 47,250 shares of BioCryst'

Summary BioCryst Pharmaceuticals Inc (BCRX) has announced that it will present new data on its oral, once-daily medication ORLADEYO® (berotralstat) at the Euro

RESEARCH TRIANGLE PARK, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. ( BCRX) today announced that new data on oral, once-daily ORLAD

Summary BioCryst Pharmaceuticals Inc (BCRX) announced new data on May 30, 2025, showcasing the effectiveness of berotralstat in reducing hereditary angioedema (

BioCryst Pharmaceuticals (BCRX) has revealed promising data from the APeX-P trial, showcasing the benefits of berotralstat in reducing hereditary angioedema (HA

**media[641244]**

Summary BioCryst Pharmaceuticals Inc (BCRX), a global biotechnology company dedicated to developing treatments for rare diseases, announced on May 27, 2025, tha

Shares of BioCryst Pharmaceuticals Inc (BCRX) surged 3.62% in mid-day trading on May 22. The stock reached an intraday high of $10.58, before settling at $10.

BioCryst Pharmaceuticals (BCRX) has revealed compelling real-world data showcasing the effectiveness of their oral, once-daily treatment, ORLADEYO, in reducing

Summary BioCryst Pharmaceuticals Inc (BCRX) released new real-world evidence on May 16, 2025, demonstrating the effectiveness of ORLADEYO® (berotralstat) in si

BioCryst Pharmaceuticals (BCRX) has announced that the U.S. Food and Drug Administration has accepted its New Drug Application for ORLADEYO, aimed at treating h

**media[625383]**

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid